Wealthedge Investment Advisors LLC boosted its position in shares of CalciMedica Inc. (NASDAQ:CALC – Free Report) by 289.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 108,291 shares of the company’s stock after purchasing an additional 80,472 shares during the period. Wealthedge Investment Advisors LLC owned 0.78% of CalciMedica worth $207,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. 180 Wealth Advisors LLC acquired a new position in CalciMedica during the 1st quarter worth $31,000. Cetera Investment Advisers grew its stake in CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in shares of CalciMedica during the first quarter valued at approximately $45,000. Renaissance Technologies LLC bought a new stake in shares of CalciMedica during the fourth quarter valued at approximately $153,000. Finally, Millennium Management LLC grew its stake in shares of CalciMedica by 30.5% during the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock valued at $255,000 after purchasing an additional 16,824 shares during the last quarter.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a research note on Thursday, May 15th.
CalciMedica Stock Performance
Shares of CalciMedica stock opened at $2.91 on Friday. The firm has a market cap of $40.65 million, a price-to-earnings ratio of -1.82 and a beta of 1.33. The stock’s 50-day moving average is $2.36 and its 200-day moving average is $2.12. CalciMedica Inc. has a one year low of $1.42 and a one year high of $5.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 5.45 and a quick ratio of 5.66.
CalciMedica (NASDAQ:CALC – Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). Equities analysts predict that CalciMedica Inc. will post -2.21 earnings per share for the current fiscal year.
CalciMedica Profile
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- Best Aerospace Stocks Investing
- 3 Restaurant Stocks That Will Outperform in Q3 and Q4
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The Midstream Energy Play That Keeps Powering Higher
- What is a Death Cross in Stocks?
- Ethereum Near All-Time High: 3 Stocks Stacking ETH in Treasuries
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
